CINECA IRIS Institutional Research Information System

VIGNA, Elisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.421
EU - Europa 1.295
AS - Asia 762
AF - Africa 8
OC - Oceania 7
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 5
Totale 4.504
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.395
CN - Cina 409
IT - Italia 386
IE - Irlanda 192
SG - Singapore 185
SE - Svezia 160
FR - Francia 122
UA - Ucraina 95
FI - Finlandia 77
GB - Regno Unito 67
DE - Germania 59
KR - Corea 49
VN - Vietnam 45
PL - Polonia 31
CA - Canada 26
ID - Indonesia 23
BE - Belgio 21
AT - Austria 18
CH - Svizzera 14
HK - Hong Kong 12
IN - India 12
JP - Giappone 12
NL - Olanda 11
ES - Italia 10
HU - Ungheria 7
RU - Federazione Russa 7
SN - Senegal 7
AU - Australia 5
EU - Europa 5
GR - Grecia 5
BR - Brasile 4
PK - Pakistan 3
PT - Portogallo 3
RO - Romania 3
TW - Taiwan 3
IR - Iran 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
AR - Argentina 1
BG - Bulgaria 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
GE - Georgia 1
HR - Croazia 1
IL - Israele 1
MO - Macao, regione amministrativa speciale della Cina 1
PH - Filippine 1
PY - Paraguay 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
TR - Turchia 1
Totale 4.504
Salva come PNG Salva come JPEG
Città #
Chandler 318
Beijing 275
Ann Arbor 262
Dublin 191
Singapore 129
Fairfield 107
Ashburn 98
Dearborn 96
Houston 80
Torino 80
Wilmington 64
Woodbridge 60
Nyköping 59
Villeurbanne 57
Jacksonville 52
Medford 52
Cambridge 51
Turin 51
Columbus 49
Princeton 47
Seattle 46
Dong Ket 37
Milan 32
Boston 26
Guangzhou 26
Pisa 26
Fremont 24
Jakarta 23
Santa Clara 22
Boardman 21
Warsaw 21
Redwood City 19
Brussels 18
Shanghai 18
Vienna 18
New York 16
San Diego 14
Nanjing 12
Toronto 12
Hangzhou 11
Buffalo 9
Rome 9
Verona 9
Los Angeles 8
Tokyo 8
Toulouse 8
Hefei 7
Helsinki 7
Palermo 7
Basel 6
Lachine 6
Norwalk 6
Silver Spring 6
Upper Marlboro 6
Washington 6
Amsterdam 5
Birmingham 5
Florence 5
Luni 5
Rochester 5
Barcelona 4
Central 4
Dallas 4
Düsseldorf 4
Edinburgh 4
Kunming 4
London 4
Menlo Park 4
Mountain View 4
Munich 4
San Francisco 4
Wroclaw 4
Zhengzhou 4
Abbiategrasso 3
Arlesheim 3
Auburn Hills 3
Boerne 3
Brescia 3
Budapest 3
Chengdu 3
Cuneo 3
Cypress 3
Naples 3
Napoli 3
Nashville 3
Ottawa 3
Paris 3
Phoenix 3
San Mateo 3
Seoul 3
Southend 3
Sydney 3
Xian 3
Alessandria 2
Assago 2
Atlanta 2
Auckland 2
Balen 2
Bangkok 2
Broomfield 2
Totale 2.879
Salva come PNG Salva come JPEG
Nome #
Targeting the oncogenic Met receptor by antibodies and gene therapy. 228
Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. 202
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. 183
Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. 169
Quiescent neuronal progenitors are activated in the juvenile guinea pig lateral striatum and give rise to transient neurons 162
Rebound effects caused by withdrawal of MET Kinase inhibitor are quenched by a MET Therapeutic antibody 161
Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody 158
CD44v6 as innovative sarcoma target for CAR-redirected CIK cells 150
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. 142
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. 135
MET/HGF co-targeting in pancreatic cancer: A tool to provide insight into the tumor/stroma crosstalk 129
Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. 127
Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. 120
"Active" cancer immunotherapy by anti-Met antibody gene transfer 117
Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy 111
CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft tissue sarcoma histotypes 104
Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib 102
Mek1 inhibition in vivo mitigates progressive cardiac concentric hypertrophy promoted by activated Met receptor. 92
Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes 90
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 85
Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. 84
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours 84
Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. 83
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET 82
A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis. 80
The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation 79
Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody 78
Hepatocyte growth factor is a regulator of monocyte-macrophage function 69
Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. 65
Molecular engineering strategies tailoring the apoptotic response to a met therapeutic antibody 64
Targeted anticancer therapy by a recombinant monovalent antibody against the MET oncogene 63
TCR gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naïve and memory T-cells without prior stimulation of endogenous TCR 62
Antibody Fragments, Compositions And Uses Thereof - granted patent (USA) 62
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers 62
Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. 61
Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors 59
MET overexpression turns human primary osteoblasts into osteosarcomas 59
Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor 59
The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. 57
A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. 53
Semaphorin 3A normalizes the tumor vasculature and impairs tumor progression in a Nrp-1-independent manner 53
Hgf/met axis induces tumor secretion of tenascin-c and promotes stromal rewiring in pancreatic cancer 53
Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products 51
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy 44
Human cord blood CD34+ progenitor cells acquire functional cardiac properties through a cell fusion process. 44
New antibody fragments, compositions and uses thereof 41
New Antibody Fragments, Compositions And Uses Thereof - granted patent (Eurasian Patent Organisation) 40
A receptor-antibody hybrid hampering MET-driven metastatic spread 37
New Antibody Fragments, Compositions And Uses Thereof - granted patent (Canada) 34
Anti-met fab-fc for the treatment of a tumor and/or metastasis 31
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma 24
Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination 17
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification 15
Abstract 3998: Preclinical efficacy of a synthetic Notch-based combinatorial immunotherapy against colorectal cancer with HER2 amplification 15
MET Oncogene Targeting for Cancer Immunotherapy 8
Totale 4.639
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.373
article - articoli 0
book - libri 0
conference - conferenze 897
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.270
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020406 0 0 0 0 43 108 69 39 43 52 31 21
2020/2021522 27 27 29 36 51 38 63 18 50 36 43 104
2021/2022824 58 53 45 76 24 47 36 29 25 56 263 112
2022/20231.002 71 83 19 78 106 246 70 92 126 20 64 27
2023/2024405 55 70 22 19 26 58 15 19 2 32 25 62
2024/2025313 14 102 80 107 10 0 0 0 0 0 0 0
Totale 4.639